Cart
0

Breast Biopsy Market by Product [Vacuum Assisted Biopsy (VAB), Core Needle Biopsy (CNB) and Fine Needle Aspiration Biopsy (FNAB)], Image Guided Technology (MRI-Guided Biopsy, Ultrasound Guided Biopsy, Mammography Guided Stereotactic Biopsy, CT-Guided Biopsy) and End User (Hospitals and Diagnostic Centers) - Global Opportunity Analysis and Industry Forecast, 2016-2023

Get 20% Free Customization In This Report
LI_171067
Pages: 170
Apr 2017 | 3727 Views
 
Author's : Garima Chandra
Tables: 50
Charts: 64
 

Breast Biopsy Market Overview:

Global Breast Biopsy Market was valued at $976.7 million in 2016, and is projected to reach at $1,420 million by 2023, growing at a CAGR of 5.3% from 2017 to 2023. Breast biopsy is a test performed to remove tissue or fluid from the suspicious area of the patient’s body, while the removed sample is further examined to check the presence of breast cancer. There are different types of biopsy procedures depending on the product, such as vacuum assisted biopsy (VAB), core needle biopsy (CNB), and fine needle aspiration biopsy (FNAB), recommended by the doctor based on the location, size, and other characteristics of the breast abnormality.

Increase in incidence of breast cancer; ageing women especially around the age 40, during menopause (are more susceptible to breast cancer); and growth in awareness regarding breast cancer screening programs drive the market growth. However, uncertain regulatory issues, infection risks associated during breast biopsy procedures, and unclear reimbursement policies are the factors limiting the market growth. Conversely, emergence of technologically advanced and minimally invasive breast biopsy devices are expected to provide lucrative opportunities in untapped market.

Global Breast Biopsy Market Segmentation

Breast Biopsy Market Segmentation

Get more information on this report : Request Sample Pages

The breast biopsy market is segmented based on product, image guided technology, end user, and geography. On the basis of product, it is categorized into vacuum-assisted biopsy (VAB), core needle biopsy (CNB), and fine needle aspiration biopsy (FNAB). Based on image guided technology, it is classified into MRI-guided biopsy, ultrasound guided biopsy, mammography guided stereotactic biopsy, CT-guided biopsy, and others. On the basis of end user, it is bifurcated into diagnostic centers and hospitals. Geographically, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Germany, Russia, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, Singapore, Philippines, and rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Israel, Saudi Arabia, South Africa, and rest of LAMEA).

Drivers, Restraints, and Opportunities

The impact of the driving factors is expected to surpass that of the restraints. Moreover, emergence of new technologies and increase in adoption of mammography-guided stereotactic biopsy are anticipated to provide new growth opportunities in the near future.

Global Breast Biopsy Market: Drivers, Restrains, and Opportunities

Breast Biopsy Market: Drivers, Restrains, and Opportunities

Get more information on this report : Request Sample Pages

The mammography-guided stereotactic biopsy segment accounted for a significant share in the global biopsy market, and is expected to maintain dominance during the forecast period.

Breast Biopsy Market by Image Guided Technology

Breast Biopsy Market by Image Guided Technology

Get more information on this report : Request Sample Pages

Breast cancer is one of the significant health issues for women globally. This is evident from the estimated number of new breast cancer cases from American Cancer Society, Inc., in 2015, which stated the newly diagnosed cancer based on age (in situ, invasive cases, and total deaths) in the U.S. In addition, more than 3.1 million women were alive on January 1, 2014, with a history of breast cancer in the U.S. alone.

Estimated Number of Female Breast Cancer Cases and Deaths by Age, U.S., 2015

Estimated Number of Female Breast Cancer Cases and Deaths by Age, U.S., 2015

Get more information on this report : Request Sample Pages

The recommendation for breast biopsy especially the mammography guided stereotactic biopsy has rapidly increased the adoption rate in the developed countries. Moreover, the rationalizing use of mammography complemented by the other breast examinations has served as a pillar for screening breast cancer for past few years driving the market growth.

The list of key players included in the report include Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.

The other players in the value chain include Zenalux Biomedical, Inc., F. Hoffmann-La Roche Ltd., OncoCyte Corporation, Laboratory Corporation of America Holdings (Labcorp), Scion Medical Technologies, Planmed Oy, Aurora Imaging Technology Inc., Carestream Health, Cardinal Health, and PerkinElmer.

Key Benefits for Stakeholders

  • This report provides an extensive analysis of the current & emerging market trends and dynamics in the global breast biopsy market.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • This report entails the detailed quantitative analysis of the current trends and future estimations to identify the prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Region- and country-wise market conditions are analyzed in the report.

Breast Biopsy Market Key Segments

By Product

  • Vacuum Assisted Biopsy (VAB)
  • Core Needle Biopsy (CNB)
  • Fine Needle Aspiration Biopsy (FNAB)

By Guided Technology

  • MRI-Guided Biopsy
  • Ultrasound Guided Biopsy
  • Mammography Guided Stereotactic Biopsy
  • CT-Guided Biopsy
  • Others

By End User

  • Diagnostic Centers
  • Hospitals

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Singapore
    • Philippines
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • Israel
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. KEY BENEFITS
1.2. KEY MARKET SEGMENTS
1.3. KEY PLAYERS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top winning strategies
3.2.2. Top investment pockets

3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK AND REIMBURSEMENT SCENARIO
3.5. TOP PLAYER POSITIONING, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Rise in incidence rate of breast cancer
3.6.1.2. Advent of novel and minimal invasive biopsy procedures
3.6.1.3. Increase in number of breast cancer screening programs
3.6.1.4. Technological advancements in breast imaging equipment

3.6.2. Restraints

3.6.2.1. Uncertain regulatory issues
3.6.2.2. Infectious risk associated with breast biopsy procedures
3.6.2.3. High cost and unclear reimbursement policies

3.6.3. Opportunities

3.6.3.1. Untapped emerging economies
3.6.3.2. Increasing awareness regarding breast cancer

Chapter: 4 GLOBAL BREAST BIOPSY MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Key market trends
4.1.2. Growth factors and opportunities
4.1.3. Market size and forecast

4.2. VACUUM ASSISTED BIOPSY (VAB)

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. CORE NEEDLE BIOPSY (CNB)

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. FINE NEEDLE ASPIRATION BIOPSY (FNAB)

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 GLOBAL BREAST BIOPSY MARKET, BY IMAGE GUIDED TECHNOLOGY

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. MRI-GUIDED BREAST BIOPSY

5.2.1. Market size and forecast

5.3. ULTRASOUND GUIDED BREAST BIOPSY

5.3.1. Market size and forecast

5.4. MAMMOGRAPHY GUIDED STEREOTACTIC BIOPSY

5.4.1. Market size and forecast

5.5. CT-GUIDED BIOPSY

5.5.1. Market size and forecast

5.6. OTHER IMAGE GUIDED BREAST BIOPSY

5.6.1. Market size and forecast

Chapter: 6 GLOBAL BREAST BIOPSY MARKET, BY END USER

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. DIAGNOSTIC CENTER

6.2.1. Market size and forecast

6.3. HOSPITAL

6.3.1. Market size and forecast

Chapter: 7 BREAST BIOPSY MARKET, BY REGION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Growth factors and opportunities
7.2.3. Market size and forecast by Country
7.2.4. Market size and forecast by Product
7.2.5. Market size and forecast by Image Guided Technology
7.2.6. Market size and forecast by End User

7.2.6.1. U.S. market size and forecast
7.2.6.2. Canada market size and forecast
7.2.6.3. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Growth factors and opportunities
7.3.3. Market size and forecast by Country
7.3.4. Market size and forecast by Product
7.3.5. Market size and forecast by Image Guided Technology
7.3.6. Market size and forecast by End User

7.3.6.1. UK market size and forecast
7.3.6.2. France market size and forecast
7.3.6.3. Germany market size and forecast
7.3.6.4. Italy market size and forecast
7.3.6.5. Spain market size and forecast
7.3.6.6. Russia market size and forecast
7.3.6.7. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Growth factors and opportunities
7.4.3. Market size and forecast by Country
7.4.4. Market size and forecast by Product
7.4.5. Market size and forecast by Image Guided Technology
7.4.6. Market size and forecast by End User

7.4.6.1. Japan market size and forecast
7.4.6.2. China market size and forecast
7.4.6.3. India market size and forecast
7.4.6.4. Australia market size and forecast
7.4.6.5. Singapore market size and forecast
7.4.6.6. Philippines market size and forecast
7.4.6.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Growth factors and opportunities
7.5.3. Market size and forecast by Country
7.5.4. Market size and forecast by Product
7.5.5. Market size and forecast by Image Guided Technology
7.5.6. Market size and forecast by End User

7.5.6.1. Brazil market size and forecast
7.5.6.2. Turkey market size and forecast
7.5.6.3. Israel market size and forecast
7.5.6.4. Saudi Arabia market size and forecast
7.5.6.5. South Africa market size and forecast
7.5.6.6. Rest of LAMEA market size and forecast

Chapter: 8 COMPANY PROFILES

8.1. HOLOGIC INC.

8.1.1. Company overview
8.1.2. Operating business segments
8.1.3. Business performance
8.1.4. Key strategic moves and developments

8.2. LEICA BIOSYSTEMS NUSSLOCH GMBH (DEVICOR MEDICAL PRODUCTS, INC.)

8.2.1. Company overview
8.2.2. Operating business segments
8.2.3. Business performance
8.2.4. Key strategic moves and developments

8.3. C. R. BARD, INC.

8.3.1. Company overview
8.3.2. Operating business segments
8.3.3. Business performance
8.3.4. Key strategic moves and developments

8.4. BECTON DICKINSON AND COMPANY

8.4.1. Company overview
8.4.2. Operating business segments
8.4.3. Business performance
8.4.4. Key strategic moves and developments

8.5. ARGON MEDICAL DEVICES

8.5.1. Company overview
8.5.2. Operating business segments
8.5.3. Business performance
8.5.4. Key strategic moves and developments

8.6. COOK MEDICAL INCORPORATED

8.6.1. Company overview
8.6.2. Operating business segments
8.6.3. Business performance
8.6.4. Key strategic moves and developments

8.7. ENCAPSULE MEDICAL DEVICES LLC.

8.7.1. Company overview
8.7.2. Operating business segments
8.7.3. Business performance
8.7.4. Key strategic moves and developments

8.8. ETHICON ENDO SURGERY (JOHNSON & JOHNSON)

8.8.1. Company overview
8.8.2. Operating business segments
8.8.3. Business performance
8.8.4. Key strategic moves and developments

8.9. INTACT MEDICAL CORPORATION

8.9.1. Company overview
8.9.2. Operating business segments
8.9.3. Business performance
8.9.4. Key strategic moves and developments

8.10. GALINI SRL

8.10.1. Company overview
8.10.2. Operating business segments
8.10.3. Business performance
8.10.4. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL BREAST BIOPSY MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 2. GLOBAL VACUUM ASSISTED BIOPSY (VAB) MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 3. GLOBAL CORE NEEDLE BIOPSY (CNB) MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL FINE NEEDLE ASPIRATION BIOPSY (FNAB) MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 5. GLOBAL BREAST BIOPSY MARKET, BY IMAGE GUIDED TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 6. GLOBAL MRI-GUIDED BREAST BIOPSY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 7. GLOBAL ULTRASOUND GUIDED BREAST BIOPSY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 8. GLOBAL MAMMOGRAPHY GUIDED STEREOTACTIC BIOPSY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 9. GLOBAL CT-GUIDED BREAST BIOPSY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL OTHER IMAGE GUIDED BREAST BIOPSY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 11. GLOBAL BREAST BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 12. GLOBAL BREAST BIOPSY MARKET FOR DIAGNOSTIC CENTER, BY REGION, 2016-2023 ($MILLION)
TABLE 13. GLOBAL BREAST BIOPSY MARKET FOR HOSPITAL, BY REGION, 2016-2023 ($MILLION)
TABLE 14. GLOBAL BREAST BIOPSY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 15. NORTH AMERICA BREAST BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 16. NORTH AMERICA BREAST BIOPSY MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 17. NORTH AMERICA BREAST BIOPSY MARKET, BY IMAGE GUIDED TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 18. NORTH AMERICA BREAST BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 19. EUROPE BREAST BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 20. EUROPE BREAST BIOPSY MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 21. EUROPE BREAST BIOPSY MARKET, BY IMAGE GUIDED TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 22. EUROPE BREAST BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 23. ASIA-PACIFIC BREAST BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 24. ASIA-PACIFIC BREAST BIOPSY MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 25. ASIA-PACIFIC BREAST BIOPSY MARKET, BY IMAGE GUIDED TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 26. ASIA-PACIFIC BREAST BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 27. LAMEA BREAST BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 28. LAMEA BREAST BIOPSY MARKET, BY PRODUCT, 2016-2023 ($MILLION)
TABLE 29. LAMEA BREAST BIOPSY MARKET, BY IMAGE GUIDED TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 30. LAMEA BREAST BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 31. HOLOGIC: COMPANY SNAPSHOT
TABLE 32. HOLOGIC: OPERATING SEGMENTS
TABLE 33. LEICA BIOSYSTEMS: COMPANY SNAPSHOT
TABLE 34. LEICA BIOSYSTEMS: OPERATING SEGMENTS
TABLE 35. C. R. BARD: COMPANY SNAPSHOT
TABLE 36. C. R. BARD: OPERATING SEGMENTS
TABLE 37. BECTON DICKINSON: COMPANY SNAPSHOT
TABLE 38. BECTON DICKINSON: OPERATING SEGMENTS
TABLE 39. ARGON: COMPANY SNAPSHOT
TABLE 40. ARGON: OPERATING SEGMENTS
TABLE 41. COOK MEDICAL: COMPANY SNAPSHOT
TABLE 42. COOK MEDICAL: OPERATING SEGMENTS
TABLE 43. ENCAPSULE MEDICAL: COMPANY SNAPSHOT
TABLE 44. ENCAPSULE MEDICAL: OPERATING SEGMENTS
TABLE 45. ETHICON: COMPANY SNAPSHOT
TABLE 46. ETHICON: OPERATING SEGMENTS
TABLE 47. INTACT MEDICAL: COMPANY SNAPSHOT
TABLE 48. INTACT MEDICAL: OPERATING SEGMENTS
TABLE 49. GALINI: COMPANY SNAPSHOT
TABLE 50. GALINI: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 1. GLOBAL BREAST BIOPSY MARKET, 2016-2023
FIGURE 2. SEGMENTATION OF GLOBAL BREAST BIOPSY MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2014-2017
FIGURE 4. TOP WINNING STRATEGIES: BY NATURE, & TYPE OF DEVELOPMENT, 2014-2017
FIGURE 5. TOP INVESTMENT POCKETS
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. TOP PLAYER POSITIONING: GLOBAL BREAST BIOPSY MARKET, 2016
FIGURE 12. U.S. BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 13. CANADA BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 15. UK BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 16. FRANCE BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 17. GERMANY BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 18. ITALY BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 19. SPAIN BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 20. RUSSIA BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 21. REST OF EUROPE BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 22. JAPAN BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 23. CHINA BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 24. INDIA BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 25. AUSTRALIA BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 26. SINGAPORE BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 27. PHILIPPINES BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 28. REST OF ASIA-PACIFIC BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 29. BRAZIL BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 30. TURKEY BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 31. ISRAEL BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 32. SAUDI ARABIA BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 33. SOUTH AFRICA BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 34. REST OF LAMEA BREAST BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 35. HOLOGIC: REVENUE, 2014-2016 ($MILLION)
FIGURE 36. HOLOGIC: REVENUE BY SEGMENT, 2016 (%)
FIGURE 37. HOLOGIC: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 38. LEICA BIOSYSTEMS: REVENUE, 2014-2016 ($MILLION)
FIGURE 39. LEICA BIOSYSTEMS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 40. LEICA BIOSYSTEMS: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 41. C. R. BARD: REVENUE, 2014-2016 ($MILLION)
FIGURE 42. C. R. BARD: REVENUE BY SEGMENT, 2016 (%)
FIGURE 43. C. R. BARD: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 44. BECTON DICKINSON: REVENUE, 2014-2016 ($MILLION)
FIGURE 45. BECTON DICKINSON: REVENUE BY SEGMENT, 2016 (%)
FIGURE 46. BECTON DICKINSON: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 47. ARGON: REVENUE, 2014-2016 ($MILLION)
FIGURE 48. ARGON: REVENUE BY SEGMENT, 2016 (%)
FIGURE 49. ARGON: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 50. COOK MEDICAL: REVENUE, 2014-2016 ($MILLION)
FIGURE 51. COOK MEDICAL: REVENUE BY SEGMENT, 2016 (%)
FIGURE 52. COOK MEDICAL: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 53. ENCAPSULE MEDICAL: REVENUE, 2014-2016 ($MILLION)
FIGURE 54. ENCAPSULE MEDICAL: REVENUE BY SEGMENT, 2016 (%)
FIGURE 55. ENCAPSULE MEDICAL: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 56. ETHICON: REVENUE, 2014-2016 ($MILLION)
FIGURE 57. ETHICON: REVENUE BY SEGMENT, 2016 (%)
FIGURE 58. ETHICON: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 59. INTACT MEDICAL: REVENUE, 2014-2016 ($MILLION)
FIGURE 60. INTACT MEDICAL: REVENUE BY SEGMENT, 2016 (%)
FIGURE 61. INTACT MEDICAL: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 62. GALINI: REVENUE, 2014-2016 ($MILLION)
FIGURE 63. GALINI: REVENUE BY SEGMENT, 2016 (%)
FIGURE 64. GALINI: REVENUE BY GEOGRAPHY, 2016 (%)

 

The breast biopsy market has witnessed sizeable growth in the recent years, owing to rise in incidence of breast cancer and increase in awareness about the screening programs for preventing breast cancer deaths. Breast cancer is the most common form of cancer, especially in the American women, and is one of the leading cause of death. Breast biopsy devices are widely adopted in comparison to open surgeries, specifically due to the minimal invasive nature of the devices, such as vacuum assisted biopsy (VAB), core needle biopsy (CNB) and fine needle aspiration biopsy (FNAB). Moreover, the adoption of advanced and image-guided biopsy devices is expected to increase due to rise in incidence of breast cancer globally. In addition, these biopsy devices offer several advantages, such as minimal invasiveness, less pain & bleeding, low chances of infection, short hospital stay, and reduced chances of other complications. Increase in incidence of cancer, growth in awareness about biopsy procedures, and heavy investment by leading companies to promote their products fuel the growth of the biopsy devices market. However, limited capital investment and lack of technical expertise are expected to hamper the market growth.

The global leaders in biopsy devices, such as C.R. Bard, Hologic, Inc., Leica Biosystems, which recently acquired Devicor, have launched several novel biopsy devices in the market. Core needle biopsies are predominantly used for performing biopsies while vacuum-assisted core breast biopsies are most popularly used breast biopsy procedure, as these allow multiple and large volume sampling of tissues with minimal invasion. These biopsies can be performed in outpatient settings and do not require prolonged healing process. Thus, breast biopsy segment is expected to dominate the market in future, owing to high market capitalization and technical advancements.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Breast Biopsy Market- Global Opportunity Analysis and Industry Forecast, 2016-2023

  • Online Only
  • $4176 $3759
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640 $4176
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540 $4709
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654 $5324
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $9280 $6960
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo